ING Group’s PDL BioPharma, Inc. PDLI Stock Holding History

ING Group’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-100,658	Closed	-$834K	–	731
2014 Q1	$834K	Sell	100,658 -182,472	-64%	-$1.56M	﹤0.01%	585
2013 Q4	$2.39M	Buy	283,130 +11,707	+4%	+$98.7K	0.01%	445
2013 Q3	$2.16M	Hold	271,423	–	–	0.01%	482
2013 Q2	$2.09M	Buy	+271,423	New	+$2.12M	0.01%	466

Other funds holding PDLI

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

AAM

Advisors Asset Management Monument, Colorado $6.56B AUM 35.09% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ING Group's PDLI Position: Q2 2014 in Review

ING Group sold out of PDL BioPharma, Inc. (PDLI) in Q2 2014, closing a stake of 100,658 shares — an estimated $834K sold.

ING Group first reported a position in PDLI in Q2 2013 and held it in 4 quarters. The position peaked at $2.39M in Q4 2013. 222 funds tracked by Wall St. Rank hold PDLI as of Q2 2014.

ING Group reported no remaining PDL BioPharma, Inc. position as of Q2 2014 after selling out during the quarter.
ING Group sold 100,658 PDL BioPharma, Inc. shares in Q2 2014, an estimated $834K.
ING Group first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 4 quarters.
ING Group's PDL BioPharma, Inc. position peaked at $2.39M in Q4 2013.
222 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q2 2014.

Based on ING Group's 13F filing for Q2 2014, filed 14 Aug 2014.